EU Stakeholders Want More Focus On Availability Of Medicines
Consultation Comments Also Highlight Transparency And Supply Chain Concerns
EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.